

GO-Dx Corporation (Aust) Ltd
A.C.N. 673 839 613
INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

GO-Dx Corporation (Aust) Ltd

1. Company details

Name of entity:	GO-Dx Corporation (Aust) Ltd
ABN:	84 673 839 613
Reporting period:	For the half year ended 31 December 2024
Previous period:	For the period 22 December 2023 (date of incorporation) to 31 December 2023

2. Results for announcement to the market

			\$
Revenues from ordinary activities	Up	100%	5,369
Loss from ordinary activities after tax attributable to the owners of GO-Dx Corporation (Aust) Ltd	Up	100%	(627,943)
Loss for the half year attributable to the owners of GO-Dx Corporation (Aust) Ltd	Up	100%	(627,943)
<i>Dividends</i>			
		Amount per security Cents	Franked amount per security Cents
Dividend for the half year ended 31 December 2024		Not applicable	Not applicable
Record date for determining entitlements to dividend		Not applicable	Not applicable

Comments

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$627,943 (31 December 2023: \$nil).

The company was incorporated on 22 December 2023 and listed on the National Stock Exchange on 12 July 2024.

Pursuant to the Initial Public Offering, the Company raised \$514,330 before costs and allotted 1,353,500 shares.

On 9 September 2024, the consolidated entity paid the balance owing of \$47,909 (S\$42,500) to Pathomics Health Pte Ltd to complete acquisition of 1.9% of the issued shares totalling \$229,265 (S\$200,000). Following a review of Pathomics Health Pte Ltd investment during the period the consolidated entity wrote off the investment in full.

3. Net tangible assets

	Reporting period \$	Previous period \$
Net tangible assets per ordinary security	<u>0.003</u>	<u>1.00</u>

4. Control gained over entities

Not applicable.

Half-year report

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Dividends

There were no dividends paid, recommended or declared during the current, or previous financial reporting period.

Dividend Reinvestment Plan:- Not applicable


8. Foreign entities

International financial reporting standards were applied to all foreign entities within the Group.

9. Audit qualification or review

The interim financial statements have been reviewed by the auditors. A copy of the review report is attached.

Signed

Signed 

Date: 14 March 2025

William Bass
Director

GO-Dx Corporation (Aust) Ltd
Corporate directory
31 December 2024

Directors	William Bass (appointed 1 October 2024) Cody Blackhurst (appointed 1 October 2024) Dr Kah Meng Lim Sah Soon Lim
Company secretary	Cody Blackhurst
Registered office Principal place of business - Australia	Level 6 505 Little Collins Street Melbourne Victoria 3000
Principal place of business - Singapore	3 Little Road CRF Building #07-02 Singapore 536982 Singapore
Share register	Automic Group Level 5 126-130 Phillip Street 66 Hay Street Perth WA 6000 Phone: 1300 808 280
Auditor	HLB Mann Judd (VIC) Partnership Level 9 550 Bourke Street Melbourne Victoria 3000
Solicitors	Moray & Agnew Level 6 505 Little Collins Street Melbourne Victoria 3000
Bankers	Westpac Group 200 Barangaroo Ave Barangaroo NSW 2000
Stock exchange listing	GO-Dx Corporation (Aust) Ltd shares are listed on the National Stock Exchange (NSX code: GD8)

GO-Dx Corporation (Aust) Ltd
Directors' report
31 December 2024

The directors present their report, together with the interim financial statements, of the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of GO-Dx Corporation (Aust) Ltd (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half year ended 31 December 2024.

Directors

The following persons were directors of GO-Dx Corporation (Aust) Ltd during the whole of the half year and up to the date of this report, unless otherwise stated:

William Bass (appointed 1 October 2024)
Cody Blackhurst (appointed 1 October 2024)
Dr Kah Meng Lim
Sah Soon Lim
Justyn Stedwell (resigned 8 October 2024)
Matthew Leonard (resigned 8 October 2024)

Principal activities

The consolidated entity is in the medical diagnostics and diagnostic technology sectors of the healthcare industry, pioneering development and innovation with regard to personalising Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity anti ageing, neural health, and specific cancers.

During the half year the principal continuing activities of the consolidated entity consisted of diagnostic treatment kit sales.

Review of operations

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$627,943 (31 December 2023: \$nil).

Significant changes in the state of affairs

On 12 July 2024 GO-Dx Corporation (Aust) Ltd completed its Initial Public Offering (IPO) raising \$514,330 before costs, and allotted 1,353,500 shares.

On 9 September 2024, the consolidated entity paid the balance owing of \$47,909 (S\$42,500) to Pathomics Health Pte Ltd to complete acquisition of 1.9% of the issued shares totalling \$229,265 (S\$200,000). Following a review of Pathomics Health Pte Ltd during the period the consolidated entity wrote off the investment in full.

There were no other significant changes in the state of affairs of the consolidated entity during the half year.

Events after the Reporting Date

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Meetings of directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the half year ended 31 December 2024, and the number of meetings attended by each director were:

	Full Board	Full Board	Remuneration	Remuneration	Finance Audit Risk Management	Finance Audit Risk Management
	Attended	Held	Attended	Held	Attended	Held
W Bass	9	9	1	1	2	2
C Blackhurst	9	9	1	1	2	2
Dr KM Lim	10	10	1	1	2	2
M Leonard	2	3	N/A	N/A	N/A	N/A
SS Lim	6	8	1	1	2	2
J Stedwell	3	3	N/A	N/A	N/A	N/A

Held: represents the number of meetings held during the time the director held office or was a member of the relevant committee.

GO-Dx Corporation (Aust) Ltd
Directors' report
31 December 2024


Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Auditor

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



William Bass
Director

14 March 2025

Auditor's independence declaration

As lead auditor for the review of the interim consolidated financial report of GO-Dx Corporation (Aust) Ltd ("the Company") and its controlled entities ("the consolidated entity") for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (b) any applicable code of professional conduct in relation to the review.

This declaration is in respect of the Company and the entities it controlled during the period.



**HLB Mann Judd
Chartered Accountants**

Melbourne
14 March 2025



**Jude Lau
Partner**

hlb.com.au

HLB Mann Judd (VIC) Partnership ABN 20 696 861 713

Level 9, 550 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001

T: +61 (0) 3 9606 3888 F: +61 (0) 3 9606 3800 E: mailbox@hlbvic.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (VIC) Partnership is a member of HLB International, the global advisory and accounting network

GO-Dx Corporation (Aust) Ltd
Contents
31 December 2024

Consolidated Condensed Statement of profit or loss and other comprehensive income	6
Consolidated Condensed Statement of financial position	7
Consolidated Condensed Statement of changes in equity	8
Consolidated Condensed Statement of cash flows	9
Notes to the interim financial statements	10
Directors' declaration	14
Independent auditor's report to the members of GO-Dx Corporation (Aust) Ltd	15
Shareholder information	17

General information

The interim financial statements cover GO-Dx Corporation (Aust) Ltd as a consolidated entity consisting of GO-Dx Corporation (Aust) Ltd and the entities it controlled at the end of, or during, the half year. The financial statements are presented in Australian dollars, which is GO-Dx Corporation (Aust) Ltd's functional and presentation currency.

The Company was incorporated on 22 December 2023. Accordingly, the comparative information included in the interim financial statements represents the period from date of incorporation to 31 December 2023 for the following statements and the affected notes:

- [i] Consolidated Condensed Statement of profit or loss and other comprehensive income
- [ii] Consolidated Condensed Statement of changes in equity
- [iii] Consolidated Condensed Statement of cash flows

GO-Dx Corporation (Aust) Ltd is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

**Registered office & principal place
of business – Australia**

Level 6
505 Little Collins Street
Melbourne Victoria 3000

Principal place of business - Singapore

3 Little Road
CRF Building # 07-02
Singapore 536982
Singapore

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the interim financial statements.

The interim financial statements were authorised for issue, in accordance with a resolution of directors.

GO-Dx Corporation (Aust) Ltd
Consolidated Condensed Statement of profit or loss and other comprehensive income
For the half year ended 31 December 2024

	Note	31 December 2024 \$	22 - 31 December 2023 \$
Revenue	3	5,369	-
Foreign exchange currency loss		(14,615)	
Other income		5,706	
Consulting and professional fees		(168,815)	-
Employee benefits expense including directors' fees		(136,701)	-
Depreciation expense		(1,097)	-
Impairment of investment	4	(229,265)	-
Occupancy expenses		(17,883)	-
Other expenses		(70,074)	-
Finance costs		(568)	-
Loss before income tax expense		(627,943)	-
Income tax expense		-	-
Loss after income tax expense for the half year		(627,943)	
Other comprehensive income/(loss)			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Exchange difference on translating foreign controlled entities		62,295	-
Other comprehensive income for the half year, net of tax		62,295	-
Total comprehensive (loss) for the half year		<u>(565,648)</u>	<u>-</u>
(Loss) for the period is attributable to:			
Non-controlling interest		-	-
Owners of GO-Dx Corporation (Aust) Ltd		(627,943)	-
Total comprehensive (loss) for the period is attributed to			
Non-controlling interest		-	-
Owners of GO-Dx Corporation (Aust) Ltd		(565,648)	-
		Cents	Cents
Basic earnings per share	11	(0.39)	-
Diluted earnings per share	11	(0.39)	

The above statement of consolidated condensed profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

GO-Dx Corporation (Aust) Ltd
Consolidated Condensed Statement of financial position
As at 31 December 2024

	Note	31 December 2024 \$	30 June 2024 \$
Assets			
Current assets			
Cash and cash equivalents		594,009	673,557
Trade and other receivables		8,733	5,229
Inventories	5	22,947	-
Other assets	4	15,933	442,886
Total current assets		<u>641,622</u>	<u>1,121,672</u>
Non-current assets			
Property, plant and equipment		3,274	4,141
Total non-current assets		<u>3,274</u>	<u>4,141</u>
Total assets		<u>644,896</u>	<u>1,125,813</u>
Liabilities			
Current liabilities			
Trade and other payables	6	158,280	308,475
Total current liabilities		<u>158,280</u>	<u>308,475</u>
Total liabilities		<u>158,280</u>	<u>308,475</u>
Net assets		<u>486,616</u>	<u>817,338</u>
Equity			
Issued capital	7	1,415,631	1,180,705
Foreign currency translation reserve		(4,400)	(66,695)
Accumulated losses		(924,711)	(296,768)
Equity attributable to the owners of GO-Dx Corporation (Aust) Ltd		<u>486,520</u>	<u>817,242</u>
Non-controlling interest		96	96
Total equity		<u>486,616</u>	<u>817,338</u>

The above statement of consolidated condensed financial position should be read in conjunction with the accompanying notes

GO-Dx Corporation (Aust) Ltd
Consolidated Condensed Statement of changes in equity
For the half year ended 31 December 2024

Consolidated	Issued capital \$	Foreign Currency Translation Reserves \$	Accumulated losses \$	Non-controlling Interest \$	Total equity \$
Balance at 22 December 2023	-	-	-	-	-
Loss for the period	-	-	-	-	-
Total other comprehensive income for the year	-	-	-	-	-
<i>Transactions with owners in their capacity as owners:</i>					
Contribution of equity, net of transaction costs	<u>2</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>2</u>
Balance at 31 December 2023	<u>2</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>2</u>
Balance at 1 July 2024	1,180,705	(66,695)	(296,768)	96	817,338
Loss after income tax expense for the half year	-	-	(627,943)	-	(627,943)
Other comprehensive income for the half year, net of tax	-	62,295	-	-	62,295
Total other comprehensive income for the year	-	62,295	(627,943)	-	(575,648)
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs (note 7)	<u>234,926</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>234,926</u>
Balance at 31 December 2024	<u>1,415,631</u>	<u>(4,400)</u>	<u>(924,711)</u>	<u>96</u>	<u>486,616</u>

The above statement of consolidated condensed changes in equity should be read in conjunction with the accompanying notes

GO-Dx Corporation (Aust) Ltd
Consolidated Condensed Statement of cash flows
For the half year ended 31 December 2024

	Note	31 December 2024 \$	22-31 December 2023 \$
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		2,431	-
Receipts from other income		10,540	-
Payments to suppliers and employees		<u>(579,151)</u>	<u>-</u>
Net cash used in operating activities		<u>(566,180)</u>	<u>-</u>
Cash flows from investing activities			
Payments for investments		<u>(47,909)</u>	<u>-</u>
Net cash used in investing activities		<u>(47,909)</u>	<u>-</u>
Cash flows from financing activities			
Proceeds from issue of shares		514,330	2
Share issue transaction costs		<u>(27,239)</u>	<u>-</u>
Net cash from financing activities		<u>487,091</u>	<u>2</u>
Net increase/(decrease) in cash and cash equivalents		(126,998)	2
Cash and cash equivalents at the beginning of the financial half year		673,557	-
Effects of exchange rate changes on cash and cash equivalents		<u>47,450</u>	<u>-</u>
Cash and cash equivalents at the end of the period		<u><u>594,009</u></u>	<u><u>2</u></u>

The above statement of consolidated condensed cash flows should be read in conjunction with the accompanying notes

Note 1. Material accounting policy information

These general purpose interim financial statements for the half-year reporting period ended 31 December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 *Interim Financial Reporting*.

These general-purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 2. Going concern

The financial statements for the period ended 31 December 2024 have been prepared on the basis that the consolidated entity is a going concern and therefore, contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business.

During the financial period ended 31 December 2024 the consolidated entity had cash outflows from operating activities of \$566,180 and incurred a net loss from operating activities of \$627,943.

The directors have reviewed the cashflow forecasts and believe that there are reasonable grounds to believe that the consolidated entity will be able to continue as a going concern due to the following factors:

- Implementing its strategy of progressively increasing the sale of diagnostic treatment kits within its target market with a view to achieving sustainable and profitable sales volume;
- Managing the consolidated entity's expenditure while recognising that the Board has discretion and the ability to selectively reduce certain discretionary type expenditure should it need to, to preserve the consolidated entity's cash balance; and
- The board of directors is continually seeking and exploring financing opportunities (both debt and equity) to ensure that the consolidated entity has sufficient funds on hand.

Accordingly, the Directors believe that the consolidated entity will be able to continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report. The financial report does not include any adjustments relating to the recoverability or classification of recorded asset amounts, nor the amounts or classification of liabilities that might be necessary should the consolidated entity not be able to continue as a going concern.

In the event that the consolidated entity is unsuccessful in implementing the above-stated initiatives, a material uncertainty exists, that may cast significant doubt on the consolidated entity's ability to continue as a going concern and its ability to recover assets and discharge liabilities in the normal course of business and at the amounts shown in the financial report.

Should the consolidated entity be unable to continue as a going concern it may be required to realise its assets and discharge its liabilities other than in the normal course of business and at amounts different from those stated in the financial statements. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount of liabilities that might be necessarily incurred should the consolidated entity be unable to continue as a going concern and meet its debts as and when they fall due.

	31 December 2024	22 - 31 December 2023
	\$	\$
Note 3. Revenue		
Trading sales	5,369	-
	<u>5,369</u>	<u>-</u>

Revenue from contracts with customers relates to the sale of goods and is recognised at a point in time. All revenue was generated in Singapore.

	31 December 2024	30 June 2024
	\$	\$
Note 4. Other Assets		
Prepayments [a]	15,933	287,828
Deposit [b]	-	175,058
	<u>15,933</u>	<u>442,886</u>

[a] Prepayments in the prior period included prepaid IPO costs that were transferred to issued capital as share issue costs after the Company was listed on the NSX on 12 July 2024.

[b] Deposit relates to the prepaid share subscription in Pathomics Health Pte Ltd. On 9 September the consolidated entity paid the balance owing of \$47,909 (S\$42,500) to complete acquisition of 1.9% of the issued shares totalling \$229,265 (S\$200,000). Following a review of Pathomics Health Pte Ltd during the period the consolidated entity wrote off the investment in full.

	31 December 2024	30 June 2024
	\$	\$
Note 5. Inventory		
Finished goods	22,947	-
	<u>22,947</u>	<u>-</u>

	31 December 2024	30 June 2024
	\$	\$
Note 6. Trade and other payables		
Trade payables	74,566	114,538
Sundry payable and accrued expenses	34,810	153,321
Accrued directors' fees	36,510	33,600
Amount due to related companies	12,394	5,729
Other payables	-	1,287
	<u>158,280</u>	<u>308,475</u>

GO-Dx Corporation (Aust) Ltd
Notes to the financial statements
31 December 2024

Note 7. Issued capital

	Consolidated			
	31 December 2024 Shares	30 June 2024 Shares	31 December 2024 \$	30 June 2024 \$
Ordinary shares - fully paid	<u>163,003,500</u>	<u>161,650,000</u>	<u>1,415,631</u>	<u>1,180,705</u>

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2024	161,650,000		1,180,705
Issue of shares	12 July 2024	1,353,500	\$0.38	514,330
Share issue transaction costs, net of tax		<u>-</u>		<u>(279,404)</u>
Balance	31 December 2024	<u>163,003,500</u>		<u>1,415,631</u>

Note 8. Related party transactions

Transactions with related parties

The following transactions occurred with related parties:

	31 December 2024 \$	22 - 31 December 2023 \$
	Sales to companies related to a director	5,368
Rental expense to companies related to a director	15,132	-
	31 December 2024 \$	30 June 2024 \$
<i>Balances to/from related parties</i>		
Trade payables to companies related to a director	(12,394)	(5,729)
Receivables from companies related to a director	5,299	4,980

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 9. Contingencies and commitments

There have been no changes to the contingencies and commitments previously disclosed in the 30 June 2024 financial statements.

GO-Dx Corporation (Aust) Ltd
Notes to the interim financial statements
31 December 2024

Note 10. Events after the reporting period

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 11. Earnings per share

	31 December 2024	22-31 December 2023
	\$	\$
Loss after income tax	627,943	-
Non-controlling interest	-	-
	<hr/>	<hr/>
Loss after income tax from continuing operations attributable to the owners of GO-Dx Corporation (Aust) Ltd	627,943	-
	<hr/>	<hr/>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>162,915,228</u>	<u>2</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u><u>162,915,228</u></u>	<u><u>2</u></u>
	Cents	Cents
Basic earnings per share	(0.39)	-
Diluted earnings per share	(0.39)	-


GO-Dx Corporation (Aust) Ltd
Directors' declaration
31 December 2024

In the directors' opinion:

- the attached interim financial statements and notes comply with the *Corporations Act 2001*, Australian Accounting Standard AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements;
- the attached interim financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2024 and of its performance for the financial half-year ended on that date; and
- based on the factors outlined in note 2 *Going Concern* of the interim financial statements, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the *Corporations Act 2001*

On behalf of the directors



William Bass
Director

14 March 2025

Independent Auditor's Review Report to the Members of GO-Dx Corporation (Aust) Ltd

Report on the interim financial report

Conclusion

We have reviewed the interim financial report of GO-Dx Corporation (Aust) Ltd ("the Company"), which comprises the consolidated condensed statement of financial position as at 31 December 2024, the consolidated condensed statement of profit or loss and other comprehensive income, the consolidated condensed statement of changes in equity and the consolidated condensed statement of cash flows for the half-year ended on that date, including material accounting policy information, and the directors' declaration, for the consolidated entity comprising the Company and the entities it controlled at the half-year end or from time to time during the half-year.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying interim financial report of the consolidated entity does not comply with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the consolidated entity in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our review of the interim financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Material Uncertainty Regarding Going Concern

We draw attention to Note 2 Going Concern in the interim financial report, which indicates that as at 31 December 2024 the consolidated entity incurred an operating loss for the period ended 31 December 2024 of \$627,943 and an operating cash outflow of \$566,180. These events or conditions, along with other matters outlined in Note 2 Going Concern, indicate that a material uncertainty exists that may cast significant doubt on the consolidated entity's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

hlb.com.au

HLB Mann Judd (VIC) Partnership ABN 20 696 861 713

Level 9, 550 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001

T: +61 (0) 3 9606 3888 F: +61 (0) 3 9606 3800 E: mailbox@hlbvic.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (VIC) Partnership is a member of HLB International, the global advisory and accounting network

Responsibility of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the interim financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the interim financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the interim financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that interim financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the consolidated entity's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of an interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



HLB Mann Judd
Chartered Accountants



Jude Lau
Partner

Melbourne
14 March 2025

GO-Dx Corporation (Aust) Ltd
Shareholder Information
31 December 2024

The shareholder information set out below was applicable as at 31 January 2025.

Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

	Ordinary shares	
	Number of holders	% of total shares issued
1 to 1,000	0	0.0
1,001 to 5,000	0	0.0
5,001 to 10,000	33	0.1
10,001 to 100,000	10	0.3
100,001 and over	70	99.6
	4,499	100.00
	0	-

Holding less than a marketable parcel

Equity security holders

Twenty largest quoted equity security holders

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares Issued
Chin Hua Peh	50,000,000	30.7
Kah Meng Lim	40,449,723	24.8
Siew Leng Seah	23,160,000	14.2
Ms Xiao Wang	7,354,206	4.5
Sah Soon Lim	4,980,000	3.1
Dr Ashraf El Masry	2,300,000	1.4
Cell Differentiation Hub Pte Ltd	2,000,000	1.2
Mr Chee Hua Tan	1,950,000	1.2
Mr Aldo Aditya Widodo	1,750,000	1.1
Mr Sah Soon Lim	1,620,000	1.0
Mr Voon Kwong Tien	1,506,500	0.9
Ms Siew Ha Phua	1,122,000	0.7
Mr Weng Seng Vincent Loh	1,005,500	0.6
Mr Francis Kee Hwee Tay	1,005,500	0.6
Ms Pick Yoke Kok	1,000,000	0.6
Ms Wai Yin Law	1,000,000	0.6
Prof Wong Kein Christopher Low	1,000,000	0.6
Ms Siok Kee Pok	1,000,000	0.6
Boo Yee Swan	1,000,000	0.6
Dr Tak Chuen Tam	1,000,000	0.6
	146,203,429	89.7

GO-Dx Corporation (Aust) Ltd
Shareholder Information
31 December 2024

Substantial holders

Substantial holders in the company are set out below:

	Ordinary shares	
	Number held	% of total shares issued
Chin Hua Peh	50,000,000	30.7
Kah Meng Lim	40,449,723	24.8
Siew Leng Seah	23,160,000	14.2

Voting rights

The voting rights attached to ordinary shares are set out below:

Ordinary shares

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.